Korro Bio (KRRO) EBIT (2018 - 2026)
Korro Bio's (KRRO) quarterly EBIT came in at -$20.4 million in Q1 2026, up 18.32% YoY from -$17.3 million in Q1 2025, and up 59.45% on a QoQ basis from -$50.4 million in Q4 2025.
Korro Bio (KRRO) EBIT (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of EBIT data on file, last reported at -$20.4 million in Q1 2026.
- Quarterly EBIT rose 18.32% year-over-year to -$20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$117.3 million (down 22.83% YoY) and the FY2025 annual result came in at -$121.9 million, down 32.58% from the prior year.
- EBIT grew to -$20.4 million in Q1 2026, from -$50.4 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $5.8 million in Q4 2022 to a low of -$50.4 million in Q4 2025.
- A 5-year average of -$22.2 million and a median of -$21.5 million in 2024 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT surged 127.19% — and 2023, when it sank 563.03%.
- Tracing KRRO's EBIT over 5 years: stood at $5.8 million in 2022, then slumped by 563.03% to -$26.9 million in 2023, then advanced by 14.33% to -$23.0 million in 2024, then tumbled by 118.73% to -$50.4 million in 2025, then jumped by 59.45% to -$20.4 million in 2026.
- The last three EBIT figures came in at -$20.4 million (Q1 2026), -$50.4 million (Q4 2025), and -$19.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | -20.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.11 Mn |
| Mar 31, 2026 | -20.44 Mn |
| Dec 31, 2025 | -50.40 Mn |
| Sep 30, 2025 | -19.24 Mn |
| Jun 30, 2025 | -27.20 Mn |
| Mar 31, 2025 | -25.02 Mn |
| Dec 31, 2024 | -23.04 Mn |
| Sep 30, 2024 | -23.29 Mn |
| Jun 30, 2024 | -24.13 Mn |
| Mar 31, 2024 | -21.45 Mn |
| Dec 31, 2023 | -26.89 Mn |
| Sep 30, 2023 | -19.15 Mn |
| Jun 30, 2023 | -18.41 Mn |
| Mar 31, 2023 | -20.09 Mn |
| Dec 31, 2022 | 5.81 Mn |
| Sep 30, 2022 | -20.28 Mn |
| Jun 30, 2022 | -21.27 Mn |
| Mar 31, 2022 | -23.26 Mn |
| Dec 31, 2021 | -21.36 Mn |
| Sep 30, 2021 | -24.99 Mn |